Cytokine Storm in Autoimmune Diseases: Immunopathogenesis, Clinical Implications, and Targeted Therapeutic Strategies

Aarti Verma; Vineeta Batra; Jayanand Jayanand

doi:10.36948/ijfmr.2026.v08i04.84656

Cytokine Storm in Autoimmune Diseases: Immunopathogenesis, Clinical Implications, and Targeted Therapeutic Strategies

Author(s)	Aarti Verma, Prof. Dr. Vineeta Batra, Prof. Dr. Jayanand Jayanand
Country	India
Abstract	Cytokine storm syndromes associated with autoimmune and autoinflammatory diseases represent a heterogeneous group of hyperinflammatory disorders characterized by dysregulated innate and adaptive immune responses, excessive cytokine production, and life-threatening systemic inflammation. From an immunological perspective, these syndromes most commonly manifest as Macrophage Activation Syndrome (MAS), secondary hemophagocytic lymphohistiocytosis (sHLH), cytokine release syndrome–like states, and fulminant hyperferritinemic syndromes. These conditions arise through a complex interplay of genetic susceptibility, immune dysregulation, and disease-specific inflammatory triggers. Key pathogenic pathways involve aberrant activation of macrophages, neutrophils, cytotoxic T lymphocytes, and inflammasome signaling, leading to excessive production of IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. This review synthesizes current mechanistic insights into cytokine storm syndromes across autoimmune and autoinflammatory diseases, with particular emphasis on immune signaling pathways, disease-specific inflammatory signatures, and emerging precision-targeted therapies. In addition, the review highlights similarities and distinctions between MAS, sHLH, and cytokine release syndromes to improve diagnostic recognition and therapeutic stratification. Although elevated cytokine levels correlate with disease severity, serum cytokine profiling alone may not reliably predict therapeutic response, emphasizing the need for integrated biomarker-based approaches. Current therapeutic strategies are increasingly shifting from broad immunosuppression to precision-targeted immunomodulation, including IL-1β blockade, IL-6 inhibition, IFN-γ neutralization, Janus kinase (JAK) inhibition with ruxolitinib, and emerging inflammasome-directed therapies. This review also discusses evolving biomarker-driven and mechanism-based treatment paradigms that may improve early diagnosis, risk stratification, and individualized therapy. A deeper understanding of the immunopathogenesis of cytokine storm syndromes may facilitate the development of more effective targeted interventions and improve outcomes in severe autoimmune hyperinflammatory diseases.
Keywords	Cytokine storm, Macrophage Activation Syndrome, Autoimmune rheumatic diseases, Systemic lupus erythematosus, Still’s disease, Cytokine release syndrome, Haemophagocytic lymphohistiocytosis, CAR-T cell therapy, Hyperinflammation, Targeted immunotherapy
Field	Medical / Pharmacy
Published In	Volume 8, Issue 4, July-August 2026
Published On	2026-08-04
DOI	https://doi.org/10.36948/ijfmr.2026.v08i04.84656

View / Download PDF File

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Cytokine Storm in Autoimmune Diseases: Immunopathogenesis, Clinical Implications, and Targeted Therapeutic Strategies

Share this